Lv4
480 积分 2022-12-13 加入
659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048
6小时前
已完结
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
6小时前
已完结
Characteristics of rare disease marketing applications associated with FDA product approvals 2006–2010
1年前
已完结
Accessing the accelerated approval pathway for rare disease therapeutics
1年前
已完结
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
1年前
已完结
Outcomes and endpoints in trials of cancer treatment: the past, present, and future
1年前
已完结
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
1年前
已完结
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
1年前
已完结
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
1年前
已完结
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
1年前
已完结
皖公网安备34019202002308
